Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Intestinal Neoplasms 3Gastrointestinal Neoplasms 3Gastrointestinal Diseases 3Colorectal Neoplasms 3Rectal Neoplasms 2Digestive System Neoplasms 2Rectal Diseases 1Osteosarcoma 1Neoplasms by Site 1Neoplasms 1Intestinal Diseases 1Digestive System Diseases 1Colonic Neoplasms 1

Interventions

Ifosfamide 5Temozolomide 4surufatinib 2irinotecan sucrosofate 2Vincristine 2Radiotherapy 2Nivolumab 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2vactosertib 1temsirolimus 1talazoparib 1silmitasertib 1selinexor 1regorafenib 1pepinemab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1lenvatinib 1etoposide phosphate 1endostar protein 1dostarlimab 1dinutuximab 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Osteosarcoma × 5,10-methylenetetrahydrofolic acid × Clear all
NCT01987102 2020-09-25

Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.

Isofol Medical AB

Phase 1/2 Completed
18 enrolled 20 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡